Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > AHA!?!

<< Previous

Bullboard Posts

Next >>

Comment by Buckwheat1965on Nov 17, 2020 10:08am

147 Views

Post# 31913712

RE:RE:RE:RE:RE:RE:AHA!?!

As I said, think what you want hahaha makes zero difference to me as I am still here and will leave when I desire and definitely not as a result of your posts. Agoracom has some good info but not as much fun. The dude makes some points over there and from what I recall he placed you on ignore so not sure why you would think I am someone who is ignoring you? Obviously I am not ignoring crusty the clown.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market